Healthtech Solutions Inc. (HLTT) Stock

About Healthtech Solutions Inc.

Healthtech Solutions Inc. operates as a life sciences firm through its various subsidiary companies. A primary area of their work involves creating innovative products for the treatment of both acute and chronic wounds, exemplified by AmnioBind. This specific offering is a placental membrane allograft designed to address severe burns and persistent wounds, such as diabetic foot ulcers. Beyond wound care, the company is also engaged in developing advanced ultrasound imaging technology that integrates artificial intelligence for image analysis, intended for applications in diagnosing and treating conditions affecting the chest and musculoskeletal system. Furthermore, Healthtech Solutions is pioneering software designed to electronically compare signals from a healthy heart rhythm with those from a damaged heart, aiming to derive a unique "curative waveform" signal. Established in 2018, the company's headquarters are located in Tuckahoe, New York.

Healthtech Solutions Inc. (HLTT) stock trades at $0.00 with a market capitalization of $10663. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, Healthtech Solutions Inc. generates a return on equity (ROE) of 101452833.33% — well above the market average, a sign of a high-quality business, return on capital employed of 115243533.33%, an operating margin of -204.85%, a net profit margin of -180.34%.